Table 2. Parasitological and clinical effects of Trypanosoma brucei rhodesiense strains on mouse.
| Parasitological and Clinical Parameters | Control | KETRI 3801 |
KETRI 2636 |
EATRO 1762 |
KETRI 3928 |
|---|---|---|---|---|---|
| Median pre-patent period (IQR) | N/A | 3(3–3) | 4(3–5) | 3(3–4) | 4.5(4–8)a |
| ✣First peak parasitaemia (dpi) | N/A | 4 | 6 | 6 | 20 |
| †Clinical signs (days) | N/A | 7 | 8 | 9 | 33 |
| % PCV change at day 14 dpi | −2.42 | −26.51 | −25.48 | −20.70 | −3.68 |
| % PCV change before extremis | −4.09 (56) | −26.51 (14) | −23.95 (28) | −17.58 (35) | −22.43 (56) |
| % Weight change | 16.21 | −24.12 | −19.75 | −17.79 | 13.84 |
| ⨤Median survival time (days) | N/A | 20 | 33 | 35 | - |
IQR: interquartile range.
dpi: days post infection.
First peak parasitaemia considered at level of ≥ antilog 7, and more often followed by reduction in parasite numbers.
Clinical signs observed include rough or poor coat condition and pallor of skin, reduced activity, hunched appearance, laboured breathing and crowding.
The values are estimated from Fig. 3.
Of the 10 mice, the pre-patent period of one animal was 17 days, and clearly an outlier.